Home > Gastroenterology > Jaw necrosis risk in cancer patients on zoledronic acid varies with dosing, oral health

Jaw necrosis risk in cancer patients on zoledronic acid varies with dosing, oral health

Journal
JAMA Oncology
Reuters Health - 24/12/2020 - In patients treated with zoledronic acid for bone metastases, the risk of osteonecrosis of the jaw (ONJ) was associated with cancer type, oral health and dosing frequency, researchers found in a recent study. Overall, almost 3% of such patients will developed ONJ within three years of treatment, they report in JAMA Oncology. When the study was initiated, "the incidence of ONJ and the risk factors for developing the condition were ill defined," Dr. Catherine Van Poznak of the University of Michigan Medical Center, in Ann Arbor, told Reuters Health by email. Based on the results, "the risk of ONJ appears to increase over time with use of zoledronic acid," she said. "Categories of patients at higher risk include those with multiple myeloma, those with pre-existing poor-dental-health history, and those who have zoledronic acid dosed more frequently than every five weeks." The findings "will aid clinicians when counseling patie...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on